# reload+after+2024-01-23 09:47:41.898648
address1§2656 State Street
city§Carlsbad
state§CA
zip§92008
country§United States
phone§619 728 4760
website§https://www.tyra.bio
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Tyra Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÅP, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies. Its lead product candidate is TYRA-300, a selective inhibitor of FGFR3 which is in Phase 1/2 clinical trial for the treatment of patients with mUC and other solid tumors. The company is also developing TYRA-300 for long-term complications associated with skeletal conditions including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes. Its product pipeline also includes TYRA-200, an FGFR1/2/3 inhibitor with potency FGFR2 fusions and molecular brake mutations for bile duct and solid tumors; FGF19+/FGFR4, a FGFR4-specific inhibitor that is active in the presence of the V550 gatekeeper and the C552 Cys mutations for liver and solid tumors; and RET, a specific inhibitor that is active in the presence of the V804 gatekeeper and the G810 solvent front mutations for the treatment of lung and thyroid cancer. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
fullTimeEmployees§38
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Todd  Harris Ph.D.', 'age': 44, 'title': 'Co-Founder, President, CEO, Secretary, Treasurer & Director', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 903325, 'exercisedValue': 0, 'unexercisedValue': 1429022}, {'maxAge': 1, 'name': 'Mr. Daniel  Bensen', 'age': 48, 'title': 'Co-Founder & COO', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 630800, 'exercisedValue': 0, 'unexercisedValue': 2216617}, {'maxAge': 1, 'name': 'Mr. Ali D. Fawaz J.D.', 'title': 'General Counsel & Secretary', 'fiscalYear': 2022, 'totalPay': 629230, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alan  Fuhrman', 'age': 66, 'title': 'Chief Financial Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert L. Hudkins Ph.D.', 'age': 68, 'title': 'Chief Technology Officer', 'yearBorn': 1955, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ronald V. Swanson Ph.D.', 'age': 60, 'title': 'Chief Scientific Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 536188, 'exercisedValue': 0, 'unexercisedValue': 298928}, {'maxAge': 1, 'name': 'Ms. Sarah  Honig', 'title': 'Vice President of Corporate Development & Strategy', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Hiroomi  Tada M.D., Ph.D.', 'age': 59, 'title': 'Chief Medical Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 519648, 'exercisedValue': 0, 'unexercisedValue': 1998199}, {'maxAge': 1, 'name': 'Dr. Piyush R. Patel Ph.D.', 'age': 58, 'title': 'Chief Development Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Amy  Conrad', 'title': 'Investor Contact', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§6
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.966
currency§USD
dateShortInterest§1702598400
forwardEps§-2.2
pegRatio§0.36
exchange§NMS
quoteType§EQUITY
shortName§Tyra Biosciences, Inc.
longName§Tyra Biosciences, Inc.
firstTradeDateEpochUtc§1631712600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c82a6c3c-220d-350b-9885-606667564179
gmtOffSetMilliseconds§-18000000
targetHighPrice§27.0
targetLowPrice§15.0
targetMeanPrice§22.2
targetMedianPrice§25.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§21.253
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
